Hospital-Acquired Infections (HAI) Diagnostics Market — 2025 Outlook
Executive summary
The HAI diagnostics market remains essential—and stubbornly steady—after the pandemic-era volatility. Depending on methodology and scope, 2024 global market estimates range from ~US$4.9B to US$8.3B, with most forecasters calling for low single-digit growth through 2030. Growth is underpinned by persistent HAI burden, antimicrobial resistance (AMR), and tightening quality requirements, while budget pressure and slower test utilization in mature markets keep a lid on upside.
Strategic Market Research
Market Research
Why this market matters
HAIs are common and costly: WHO and CDC data continue to show substantial prevalence—~1 in 10 patients affected globally and ~1 in 31 U.S. hospital patients on any given day—sustaining steady demand for rapid, accurate diagnostics.
World Health Organization CDC AMR intensifies the need for fast results: WHO’s 2024 IPC report highlights heavy AMR involvement in HAIs, with hundreds of millions of cases globally making appropriate, timely testing critical for stewardship.
World Health Organization
CIDRAP
Regulators are raising the bar: Updated CLIA rules refine proficiency testing and quality expectations; new CLIA-waived tests continue to expand near-patient options. In Europe, ongoing IVDR implementation keeps pressure on evidence and performance.
McDermott Centers for Medicare & Medicaid Services +1 PMC
Market size & growth (triangulated view)
Different analyst lenses (scope of infections covered, inclusion of consumables/instruments, and settings beyond acute care) yield a spread:
Strategic Market Research: US$4.9B (2024); 7.8% CAGR to US$8.2B (2030).
Strategic Market Research
Global Industry Analysts (GIA): US$8.3B (2024); ~1.0% CAGR to US$8.8B (2030).
Know More About Medical Packaging Market Download Sample Report : https://m2squareconsultancy.com/reports/hospital-acquired-infections-diagnostics-market
Purchase a Copy of https://m2squareconsultancy.com/purchase/45
Market Research
Read this as a stable, mid-single-digit demand story in developing regions and flat-to-modest growth in mature markets. Regional cuts from Grand View show North America ~US$1.17B (2024) with ~1.1% CAGR (2025-2030); APAC expected to post the fastest CAGR from a smaller base.
Grand View Research +1 Demand drivers
Persistent HAI burden & surveillance mandates (e.g., NHSN in the U.S., ECDC point-prevalence work in the EU).
- CDC
ECDC - AMR stewardship: faster ID and resistance markers shorten time-to-effective therapy.
World Health Organization
Operational pressures: limited staffing favors multiplex panels and integrated sample-to-answer systems. (Industry trend reflected across market reports.)
Strategic Market Research
Market Research
Regulatory momentum: CLIA updates and ongoing IVDR drive adoption of validated, quality-assured diagnostics.
McDermott
Headwinds
Tighter hospital budgets and utilization normalization vs. pandemic peaks (weighs on instrument placements).
Market Research
Evidence & compliance costs under IVDR/CLIA updates, particularly for LDTs and smaller IVD players.
PMC
McDermott
Reimbursement variability for advanced molecular and syndromic tests outside of sepsis/respiratory anchors. (Reflected in muted growth forecasts for instruments.)
Market Research
Segmentation snapshot
By test type
Conventional (culture, microscopy, basic immunoassay): Largest revenue share in 2024; entrenched workflows and low cost.
Molecular (PCR/NAAT, syndromic panels): Fastest-growing segment as labs seek speed and sensitivity.
Grand View Research
By infection / clinical context
Catheter-associated UTIs, C. difficile, MRSA/ESKAPE organisms, ventilator-associated pneumonia, and surgical site infections dominate volumes; pneumonia and ICU-centric panels show higher growth.
Statifacts
By product
Consumables (reagents, panels, media) dominate revenue;
Instruments grow slower from a large installed base.
Market Research
By end user
Acute-care hospital labs and reference labs lead; POC/near-patient expands where CLIA-waived options exist.
Centers for Medicare & Medicaid Services
Regional
North America: Largest share; slow growth, high compliance burden.
Grand View Research
Europe: Stable demand; IVDR drives consolidation towards well-validated assays.
PMC
APAC: Fastest growth on capacity build-out and aging demographics.
Grand View Research
Technology & product trends to watch
Syndromic molecular panels for GI, bloodstream, and lower respiratory infections to shorten diagnostic odysseys. (Growth narratives across market sources.)
Strategic Market Research
Market Research
Rapid, CLIA-waived NAAT at or near the bedside for early isolation decisions and antibiotic stewardship.
Centers for Medicare & Medicaid Services
AI-assisted microbiology (automated plate reading, colony picking) to offset staffing gaps—paired with MALDI-TOF and rapid AST. (Directionally consistent with quality/proficiency emphasis.)
McDermott
Data-driven IPC: tighter linkage between diagnostics data and infection prevention dashboards in line with CDC progress-reporting.
CDC
Competitive landscape (illustrative)
A mix of diversified IVD giants and microbiology specialists:
Roche, Abbott, Thermo Fisher, BD, bioMérieux, Danaher/Cepheid, Hologic—broad test menus and strong service footprints.
Regional players and niche innovators fill gaps in rapid AST, carbapenemase detection, and environmental surveillance. (Consolidated from multi-source market coverage.)
Strategic Market Research
Market Research
Regulation & policy notes
CLIA 2024 final rule changes tighten proficiency testing and quality expectations—relevant to labs running HAI assays and to manufacturers supporting QC.
McDermott
New CLIA-waived tests (2024–2025) broaden near-patient infectious-disease testing; coding guidance matters for adoption.
Centers for Medicare & Medicaid Services
Surveillance & benchmarking: CDC’s 2023 HAI Progress Report and ECDC’s 2022–2023 PPS keep pressure on facilities to document performance and invest in capable diagnostics.
CDC
ECDC
Strategic takeaways
Plan for steady, not spectacular, growth: Budget for low single-digit CAGR globally with APAC outgrowing NA/EU. Calibrate instrument placements to consumables pull-through.
Grand View Research +1 Market Research
Lead with time-to-result and stewardship value: Quantify LOS reduction, isolation optimization, and targeted therapy benefits in bids. Link to AMR/IPC metrics.
World Health Organization
De-risk compliance: Build CLIA/IVDR readiness into product and lab SOPs; support sites with PT, QC, and documentation.
McDermott
PMC
Meet the lab where it is: Offer hybrid menus—retain conventional methods where cost is king, and expand molecular where turnaround is critical.
Grand View Research
Appendix: burden benchmarks you can cite
- Global: “~1 in 10 patients affected by HAI” (WHO).
World Health Organization - U.S.: “~1 in 31 hospital patients has at least one HAI” (CDC).
CDC - EU (acute care): 2022–2023 point-prevalence updates (ECDC).
ECDC
Related Reports Links :
https://m2squareconsultancy.com/reports/syringe-infusion-pumps-market
https://m2squareconsultancy.com/reports/drug-discovery-outsourcing-market
https://m2squareconsultancy.com/reports/e-pharmacy-market
https://m2squareconsultancy.com/reports/healthcare-information-systems-market
https://m2squareconsultancy.com/reports/edible-oil-market
https://m2squareconsultancy.com/reports/smart-lock-market
https://m2squareconsultancy.com/reports/syringe-infusion-pumps-market
https://m2squareconsultancy.com/reports/organic-personal-care-products-market
https://m2squareconsultancy.com/reports/portable-power-station-market
To Summarize the Key Highlights of this Report:
Opportunities
- Utility-scale grid storage and energy-as-a-service models.
- Distributed residential & community energy storage.
- EV charging infrastructure and vehicle-to-grid (V2G) applications.
- Circular battery economy—local cell manufacturing and recycling.
Strategic Outlook
- Focus on scaling up domestic production and recycling to reduce import dependence.
- Leverage AI-powered energy management platforms.
- Expand utility and behind-the-meter deployments to meet renewable integration needs.
- Invest in next-generation chemistries to improve performance and lower lifecycle costs.
About m2squareconsultancy :
We are a purpose-driven market research and consulting company passionate about turning data into direction. Founded in 2023, we bring together researchers, strategists, and data scientists who believe that intelligence isn’t just about numbers, it’s about insight that sparks progress.
We cater to a wide range of industries by delivering customized solutions, strategic insights, and innovative support that help organizations grow, adapt, and lead in their respective sectors. Here’s a brief overview of key industries we work with
Contact Us:
Email: sales@m2squareconsultancy.com
Phone (IN): +91 80978 74280
Phone (US): +1 929 447 0100
